$6.42 Million is the total value of Copernicus Capital Management, LLC's 15 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $940,000 | -92.5% | 10,719 | -93.5% | 14.65% | +22.4% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $729,000 | -94.0% | 3,085 | -93.1% | 11.36% | -2.6% |
| BMY | Sell | BRISTOL-MYERS SQUIBB CO | $703,000 | -94.5% | 11,327 | -94.7% | 10.96% | -10.6% |
| ABBV | Sell | ABBVIE INC | $501,000 | -96.1% | 4,676 | -96.8% | 7.81% | -36.9% |
| TDOC | Sell | TELADOC HEALTH INC | $389,000 | -91.7% | 1,944 | -91.0% | 6.06% | +35.0% |
| IQV | Sell | IQVIA HLDGS INC | $375,000 | -94.0% | 2,094 | -94.7% | 5.84% | -1.3% |
| GWPH | Sell | GW PHARMACEUTICALS PLCads | $322,000 | -93.7% | 2,788 | -94.7% | 5.02% | +3.1% |
| TGTX | Sell | TG THERAPEUTICS INC | $304,000 | -88.0% | 5,847 | -93.8% | 4.74% | +95.7% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $296,000 | -89.0% | 3,089 | -89.0% | 4.61% | +79.9% |
| FATE | Sell | FATE THERAPEUTICS INC | $295,000 | -95.2% | 3,240 | -97.9% | 4.60% | -21.2% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $287,000 | -95.5% | 3,740 | -95.6% | 4.47% | -26.6% |
| TBIO | Sell | TRANSLATE BIO INC | $223,000 | -92.8% | 12,091 | -94.7% | 3.48% | +17.8% |
| EIGR | Exit | EIGER BIOPHARMACEUTICALS INC | $0 | – | -238,151 | -100.0% | -1.85% | – |
| ACCD | Exit | ACCOLADE INC | $0 | – | -50,000 | -100.0% | -1.85% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -278,416 | -100.0% | -1.92% | – |
| RVMD | Exit | REVOLUTION MEDICINES INC | $0 | – | -81,000 | -100.0% | -2.68% | – |
| RCUS | Exit | ARCUS BIOSCIENCES INC | $0 | – | -171,982 | -100.0% | -2.81% | – |
| MYOK | Exit | MYOKARDIA INC | $0 | – | -42,186 | -100.0% | -5.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC | 15 | Q2 2021 | 28.6% |
| THERMO FISHER SCIENTIFIC INC | 10 | Q3 2021 | 13.8% |
| ZOETIS INC | 10 | Q1 2020 | 13.0% |
| FATE THERAPEUTICS INC | 9 | Q3 2021 | 13.7% |
| ILLUMINA INC | 9 | Q4 2019 | 11.8% |
| BIOMARIN PHARMACEUTICAL INC | 8 | Q3 2021 | 14.7% |
| BRISTOL-MYERS SQUIBB CO | 8 | Q4 2020 | 12.2% |
| INTUITIVE SURGICAL INC | 7 | Q2 2019 | 11.8% |
| STRYKER CORP | 7 | Q2 2019 | 11.6% |
| IQVIA HLDGS INC | 7 | Q4 2020 | 8.2% |
View Copernicus Capital Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-16 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-14 |
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
View Copernicus Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.